NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $63.93 +0.58 (+0.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$63.55 -0.38 (-0.59%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ANI Pharmaceuticals Stock (NASDAQ:ANIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$62.68▼$64.3850-Day Range$57.79▼$68.0452-Week Range$52.50▼$77.00Volume318,815 shsAverage Volume303,297 shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/APrice Target$78.88Consensus RatingBuy Company Overview ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 247th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.07% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -50.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -50.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.83% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.48 Percentage of Shares Shorted9.83% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.69 News SentimentANI Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $345,222.00 in company stock.Percentage Held by Insiders11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ETAugust 1 at 7:03 AM | globenewswire.comANI Pharmaceuticals (NASDAQ:ANIP) pulls back 4.3% this week, but still delivers shareholders strong 16% CAGR over 5 yearsJuly 31 at 6:55 PM | finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI PharmaceuticalsJuly 30 at 2:45 AM | finance.yahoo.comANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering ValueJuly 28, 2025 | seekingalpha.comANI Pharmaceuticals (ANIP) Receives a Hold from Truist FinancialJuly 27, 2025 | theglobeandmail.comANI Pharmaceuticals reports results from clinical trial of IluvienJuly 24, 2025 | msn.comANI Pharmaceuticals Reports on NEW DAY Clinical Trial ResultsJuly 23, 2025 | tipranks.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.28 at the start of the year. Since then, ANIP shares have increased by 15.6% and is now trading at $63.93. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings results on Friday, May, 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The firm's quarterly revenue was up 43.4% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional investors include William Blair Investment Management LLC (2.26%), Aberdeen Group plc (1.69%), Mizuho Markets Americas LLC (0.98%) and Teacher Retirement System of Texas (0.68%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Antonio R Pera and Renee P Tannenbaum. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/09/2025Today8/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Price Target for ANI Pharmaceuticals$78.88 High Price Target$86.00 Low Price Target$65.00 Potential Upside/Downside+23.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.27) Trailing P/E RatioN/A Forward P/E Ratio16.56 P/E GrowthN/ANet Income-$18.52 million Net Margins-3.12% Pretax Margin-4.09% Return on Equity21.35% Return on Assets7.52% Debt Debt-to-Equity Ratio1.46 Current Ratio2.66 Quick Ratio1.98 Sales & Book Value Annual Sales$614.38 million Price / Sales2.25 Cash Flow$7.67 per share Price / Cash Flow8.34 Book Value$19.11 per share Price / Book3.35Miscellaneous Outstanding Shares21,660,000Free Float19,258,000Market Cap$1.38 billion OptionableOptionable Beta0.61 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ANIP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.